Yu Qing Huang
Net worth: 20 709 $ as of 2026-08-30
Net worth: 20 709 $ as of 2026-08-30
Yu Qing Huang is Chief Financial Officer & Executive Director at Cutia Therapeutics since 2022.
Formerly, Mr. Huang was an Analyst at Harvest Global Investments Ltd. from 2020 to 2021 and Chief Financial Officer & Business Officer at Kintor Pharmaceutical Ltd. from 2018 to 2019.
Education includes an undergraduate degree from Fudan University, conferred in 2014.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CUTIA THERAPEUTICS 0.02% | 2025-11-02 | 85,000 ( 0.02% ) | 20 709 $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| CUTIA THERAPEUTICS | Director of Finance/CFO | 2021-05-09 |
| Companies | Position | End |
|---|---|---|
Harvest Global Investments Ltd.
Harvest Global Investments Ltd. Investment ManagersFinance HGI is an active, prudent manager which has an investment focus largely on Asia, in certain cases predominantly on China, with limited amounts of investment in other markets. They may invest client assets across a range of investment classes, but, generally, investment focuses on equity and fixed income securities. The firm has a well-rounded fundamental research-driven approach, with a team of bottom-up analysis focuses on sector & company research and a team of top-down strategist focuses on global macro and market trend analysis. | Corporate Officer/Principal | 2021-04-30 |
| KINTOR PHARMACEUTICAL LIMITED | Director of Finance/CFO | 2019-09-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Fudan University
Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvest Global Investments Ltd.
Harvest Global Investments Ltd. Investment ManagersFinance HGI is an active, prudent manager which has an investment focus largely on Asia, in certain cases predominantly on China, with limited amounts of investment in other markets. They may invest client assets across a range of investment classes, but, generally, investment focuses on equity and fixed income securities. The firm has a well-rounded fundamental research-driven approach, with a team of bottom-up analysis focuses on sector & company research and a team of top-down strategist focuses on global macro and market trend analysis. | Finance |
Kintor Pharmaceutical Ltd.
Kintor Pharmaceutical Ltd. BiotechnologyHealth Technology Provides research and development of prostate, breast & liver cancer drugs services | Health Technology |
Cutia Therapeutics
Cutia Therapeutics Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing and marketing of dermatology based biopharmaceutical products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions